Singular Research restated their buy rating on shares of Amyris Inc. (NASDAQ:AMRS) in a research report report published on Wednesday morning. The brokerage currently has a $2.80 price target on the stock.

Separately, Zacks Investment Research raised Amyris from a hold rating to a buy rating and set a $0.50 target price on the stock in a research report on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $2.66.

Amyris (NASDAQ:AMRS) opened at 0.5289 on Wednesday. Amyris has a 12 month low of $0.31 and a 12 month high of $2.57. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $0.64. The firm’s market capitalization is $124.30 million.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. The firm earned $9.60 million during the quarter, compared to the consensus estimate of $15.23 million. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.47) earnings per share. On average, equities analysts forecast that Amyris will post ($0.20) EPS for the current year.

Several institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. purchased a new position in Amyris during the first quarter valued at approximately $269,000. Geode Capital Management LLC increased its position in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares during the last quarter. 35.68% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.